arrow
M

Marie C. Béné

Nantes University Hospital
H指数:69
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups

慢性淋巴细胞白血病初始免疫化疗后的来那度胺维持治疗——ALLG和FILO国际III期CLL6研究RESIDUUM部分的最终分析

2026-09-210
OAAI
Age‐adapted chemotherapy and MRD‐oriented transplant for Ph-negative acute lymphoblastic leukemia - GRAALL-2014 trial

年龄适应化疗和微小残留病导向移植治疗Ph阴性急性淋巴细胞白血病——GRAALL-2014试验

Blood
IF23.1
2025-10-280
PRE
Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results

达拉妥单抗-硼替佐米-沙利度胺-地塞米松用于新诊断的骨髓瘤:CASSIOPEIA微小残留病结果

Blood
IF23.1
2025-03-260
OA
Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation?
2024-07-080
OAAI
Pre-graft vaccination or infection do not decrease COVID-19 infections in recipients of allogeneic stem cell transplantation vaccinated and/or protected by immunotherapy after transplant

移植前疫苗接种或感染不会减少移植后免疫疗法接种和/或保护的异基因干细胞移植受者的新型冠状病毒肺炎感染

2024-07-080
OAAI
Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide
2024-01-022
PRE
CAR virus receptor mediates erythroid differentiation and migration and is downregulated in MDS
LEUKEMIA
IF13.4
2023-09-060
OA
Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis
2023-01-1917
OAAI
Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study

正电子发射断层扫描/计算机断层扫描在仙后座可移植的新诊断多发性骨髓瘤患者中的预后价值: CASSIOPET研究

2022-10-2010
OAAI
Therapy-related Myeloid Neoplasms in Patients With Chronic Lymphocytic Leukemia Who Received FCR/FC as Frontline Therapy
2022-06-012
OAAI
B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

B细胞再生障碍是同种异体造血干细胞移植受者接种BNT162b2 mRNA SARS-CoV-2疫苗后体液反应差的最有力预测指标

2022-05-0110
OAAI